Loading stock data…
BDTX
$2.60-0.05 (-1.89%)
Market ClosedLast close May 1
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Black Diamond Therapeutics, Inc. in the Healthcare sector is trading at $2.60. The stock is currently 47% below its 52-week high of $4.94, remaining 11.9% below its 200-day moving average. Technical signals show neutral RSI of 46 and bearish MACD signal, explaining why BDTX maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 46) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.60
Potential Upside
162.8%
Whystock Fair Value$6.83
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$191.92M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
8.59
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.39
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.88%
Volume
Today's trading volume
757,951
Recent News
Implied Volatility Surging for Black Diamond Therapeutics Stock Options
Investors need to pay close attention to BDTX stock based on the movements in the options market lately.
BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize
Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistance and CNS metastases as key edge in crowded lung cancer market.
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right
Black Diamond Therapeutics hinges on silevertinib, with 2026 data on progression-free survival and durability set to determine whether its single-asset story can justify upside.
Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks
BDTX rides on silevertinib, with 2026 durability data set to test early NSCLC efficacy and CNS signals, making upcoming readouts a decisive swing factor.
Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?
Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.